Histone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders
| dc.contributor.author | Kajal Thapa | |
| dc.contributor.author | Savir Kumar | |
| dc.contributor.author | Anurag Sharma | |
| dc.contributor.author | Sandeep Arora | |
| dc.contributor.author | Amarjot Kaur Grewal | |
| dc.contributor.author | Thakur Gurjeet Singh | |
| dc.date.accessioned | 2025-12-17T09:50:54Z | |
| dc.date.available | 2025-12-17T09:50:54Z | |
| dc.date.issued | 2017-11-02 | |
| dc.description.abstract | Epigenetic modification acetylation or deacetylation of histone considered as an important element in various disorders. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are the enzymes which catalyse the acetylation and deacetylation of histone respectively. It helps in regulating the condensation of chromatin and transcription of genes. Lysine acetylation and deacetylation present on the nucleosomal array of histone is the key factor for gene expression and regulation in a normal working living cell. Modification in histone protein will lead to the development of cancer and can cause various neurodegenerative disorders. To safeguard the cells or histone proteins from these diseases histone deacetylase inhibitors are used. In this review, the main focus is upon the role of histone deacetylases inhibitors in various diseases. | |
| dc.identifier.issn | 2321-2217 | |
| dc.identifier.issn | 2321-2225 | |
| dc.identifier.other | https://doi.org/10.15415/jptrm.2017.52014 | |
| dc.identifier.uri | https://demodspace.chitkara.edu.in/handle/123456789/214 | |
| dc.language.iso | en | |
| dc.publisher | Chitkara University Publications | |
| dc.subject | Epigenetic | |
| dc.subject | Histone | |
| dc.subject | Acetylation | |
| dc.subject | Deacetylation | |
| dc.subject | Lysine | |
| dc.subject | Histone deacetylases inhibitors | |
| dc.title | Histone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders | |
| dc.type | Article |